Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.

Trevena, Inc.

Trevena, Inc. is a biopharmaceutical company that focuses on delivering medicines for patients with central nervous system disorders. The company has one FDA-approved product, OLINVYK® (oliceridine) injection, and several investigational drug candidates.

NASDAQ:TRVN

Trevena, Inc.

Last Close

4.01

25/09 14:16

Market Cap

4.12M

Beta: 2.05

Volume Today

2.77K

Avg: 104.81K

PE Ratio

−0.18

PFCF: −0.22